Malaria Vaccine Market Size, Share, Growth, Trends, and Global Industry Analysis: By Type of Vaccine (Protein Vaccine, DNA Vaccines, Others), By Target (Pre-Erythrocytic Stage, Erythrocytic Stage, Combined Vaccines), By End user (Hospitals, Vaccination Centres, Others) and Region

Malaria Vaccine Market size was valued at US$ 81.51 billion in 2023 and is expected to reach US$ 239.84 million by 2028, at a significant CAGR of 33% from 2024-2030. Malaria is an infectious parasitic disease transmitted by a vector, female anopheles mosquito. Malaria produces recurrent attack of fever and chills. Malaria may lead to chronic conditions often death. Malaria may lead to several complications such as respiratory distress, severe headache and others.

Generally, malaria is diagnosed by the blood tests by investigating symptoms and presence of parasite in blood. Malaria diseases are widely spread in tropical and subtropical regions around the equator. Malaria's prevalence in tropical nations has been a source of concern for the entire world, causing millions of fatalities during the last ten years. Vaccine development is an essential component of effective intervention control.

In recent years, there has been a lot of study into new vaccine options. A diversified pipeline has been studied, based on ongoing malaria life-cycle research. Understanding the biology of the deadly human malaria parasites Plasmodium falciparum and Plasmodium vivax is critical for expanding opportunities in the malaria vaccine industry. New options in the malaria vaccine business have opened up thanks to generations of pre-erythrocytic vaccinations. This has sparked a flurry of interest from biotech firms. RTS,S/AS01 (RTS,S) is the most thoroughly investigated vaccine option for P. falciparum malaria prophylaxis.